In summary, we provided evidence that peripherally targeting CB1R and its action on HVACCs, especially Cav1.1 in the SM, could be therapeutically advantageous for obesity treatment. The gene discussed is CACNA1S; the disease is obesity due to melanocortin 4 receptor deficiency.